Persistent induction of apoptosis and suppression of mitosis as the basis for curative therapy with S-1, an oral 5-fluorouracil prodrug in a colorectal tumor model

Clinical Cancer Research

Volumn 5, Issue 2, 1999, Pages 267-274

  Cao, Shousong ^a   Lu, Kun ^a   Tóth, Karoly ^a   Slocum, Harry K ^a   Shirasaka, Tetsuhiko ^b   Rustum, Youcef M ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b TAIHO PHARMACEUTICAL CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE; 5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; OXONATE POTASSIUM; TEGAFUR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG SELECTIVITY; ENZYME INHIBITION; FEMALE; MITOSIS; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; TUMOR REGRESSION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; DRUG COMBINATIONS; FEMALE; FLUOROURACIL; MITOSIS; NEOPLASM TRANSPLANTATION; OXONIC ACID; PRODRUGS; PYRIDINES; RATS; RATS, INBRED F344; TEGAFUR; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 0033011951     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Rustum, Y. M., Trave, F., Zakrzewski, S. F., Petrelli, N., Herrera, L., Mittelman, A., Arbuck, S. G., and Creaven, P. J. Biochemical and pharmacologic basis for potentiation of 5-fluorouracil action by leucovorin. NCI Monogr., 5: 165-170, 1987.
2. Laufman, L. R., Krzeczowski, K. A., Roach, R., and Segal, M. Leucovorin plus 5-fluorouracil: an effective treatment for metastatic colon cancer. J. Clin. Oncol., 15: 1394-1400, 1987.
3. Advanced Colorectal Cancer Meta-analysis Project: modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer -evidence in terms of response rate. J. Clin. Oncol., 10: 896-903, 1992.
4. Petrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Emrich, L. J., and Mittelman, A. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J. Clin. Oncol., 5: 1559-1565, 1987.
5. Petrelli, N., Douglass, H. O. J., Herrera, L., Russell, D., Stablein, D. M., Bruckner, H. W., Mayer, R. J., Schinella, R., Green, M. D., Muggia, F. M., Megibow, A., Greenwald, E. S., Bukowski, R. M., Harris, J., Levin, B., Gaynor, E., Loutfi, A., Kaiser, M. H., Barkin, J. S., Benedetto, P., Woolley, P. V., Nauta, R., Weaver, D. W., and Leichman, L. P. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J. Clin. Oncol., 7: 1419-1426, 1989.
6. Poon, M. A., O'Connell, M. J., Wieand, H. S., Krook, J. E., Gerstner, J. B., Tschetter, L. K., Levitt, R., Kardinal, C. G., and Mailliard, J. A. Biochemical modulation of fluorouracil with leucovorin: confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J. Clin. Oncol., 9: 1967-1972, 1991.
7. Lokich, J. J., Ahlgren, J. D., Gullo, J. J., Philips, J. A., and Fryer, J. G. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. J. Clin. Oncol., 7: 425-432, 1989.
8. Barbounis, V. P., Kalofonos, H. P., Munro, A. J., McKenzie, C. G., Sackier, J., M., and Epenetos, A. A. Treatment of colorectal cancer and other malignancies with continuous infusion of 5-fluorouracil. Anticancer Res., 9: 33-40, 1989.
9. Jackman, A. L., and Calvert, A. H. Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol., 6: 871-881, 1995.
10. Jackman, A. L., Farrugia, D. C., Gibson, W., Kimbell, R., Harrap, K. R., Stephens, T. C., Azab, M., and Boyle, F. T. ZD1694 (Tomudex): a new thimidylate synthase inhibitor with activity in colorectal cancer. Eur. J. Cancer, 31A: 1277-1282, 1995.
11. Fraile, R. J., Baker, L. H., Buroker, T. R., Horwitz, J., and Vaitkevicius, V. K. Pharmacokinetics of 5-fluorouracil administered orally, by rapid intravenous and by slow infusion. Cancer Res., 40: 2223-2228, 1980.
12. Heggie, G. D., Sommadoss, J-P., Gross, D. S., Huster, W. J., and Diasio, R. B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res., 47: 2203-2206, 1987.
13. Diasio, R. B., and Harris, B. E. Clinical pharmacology of 5-fluorouracil. Clin. Pharmacokinet., 16: 215-237, 1989.
14. Spiegelman, S., Nayak, R., Sawyer, R., Stolfi, R., and Martin, D. Potentiation of the antitumor activity of 5-FU by thymidine and its correlation with the formation of (5FU)RNA. Cancer (Phila.), 45: 1129-1134, 1980.
15. Nord, L. D., Stolfi, R. L., and Martin, D. S. Biochemical modulation of 5-fluorouracil with leucovorin or delayed uridine rescue: correlation of antitumor activity with dosage and FUra incorporation into RNA. Biochem. Pharmacol., 43: 2543-2549, 1992.
16. Evans, R. M., Laskin, J. D., and Hakala, M. T. Assessment of growth-limiting events caused by 5-fluorouracil in mouse cells and in human cells. Cancer Res., 40: 4113-4122, 1980.
17. Houghton, J. A., Houghton, P. J., and Wooten, R. S. Mechanism of induction of gastrointestinal toxicity in the mouse by 5-fluorouracil, 5-fluorouridine, and 5-fluoro-2′-deoxyuridine. Cancer Res., 39: 2406-2413, 1979.
18. Shirasaka, T., Shimamoto, Y., and Fukushima, M. Inhibition by oxonic acid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res., 53: 4004-4009, 1993.
19. Shirasaka, T., Nakano, K., Takechi, T., Satake, H., Uchida, J., Fujioka, A., Saito, H., Okabe, H., Oyama, K., Takeda, S., Unemi, N., and Fukushima, M. Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res., 56: 2602-2606, 1996.
20. Cao, S., Frank, C., Shirasaka, T., and Rustum, Y. M. 5-Fluorouracil prodrug: role of anabolic and catabolic pathway modulation in therapy of colorectal cancer. Clin. Cancer Res., 1: 839-845, 1995.
21. Pazdur, R., Lassere, Y., Rhodes, V., Ajani, J. A., Sugarman, S. M., Patt, Y. Z., Jones, D. V., Jr., Marcowitz, A. B., Abbruzzese, J. L., Bready B., and Levin, B. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J. Clin. Oncol., 12: 2296-2300, 1994.
22. Cao, S., Rustum, Y. M., and Spector, T. 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma. Cancer Res., 54: 1507-1510, 1994.
23. Baccanari, D. P., Davis, S. T., Knick, V. C., and Spector, T. 5-Ethynyluracil (776C85): a potent modulator of the pharmacokinetics and antitumor efficacy of 5-fluorouracil. Proc. Natl. Acad. Sci. USA, 90: 11064-11068, 1993.
24. Baker, S. D., Khor, S. P., Adjei, A. A., Doucette, M., Spector, T., Donehower, R. C., Grochow, L. B., Sartorius, S. U., Noe, D. A., Hohneker, J. A., and Rowinsky, E. K. Pharmacokinetic, oral bioavailability, and safety study of fluorouracil in patients treated with 776C85, an inactivator of dihydropyrimidine dehydrogenase. J. Clin. Oncol., 14: 3085-3096, 1996.
25. Cao, S., Baccanari, D. P., Joyner, S. S., Davis, S. T., Rustum, Y. M., and Spector, T. 5-Ethynyluracil (776C85): effects on the antitumor activity and pharmacokinetics of tegafur, a prodrug of 5-fluorouracil. Cancer Res., 55: 6227-6230, 1995.
26. Shirasaka, T., Shimamato, Y., Ohshimo, H., Yamaguchi, M., Kato, T., Yonekura, K., and Fukushima, M. Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs, 7: 548-557, 1996.
27. Tatsumi, K., Fukushima, M., Shirasaka, T., and Fujii, S. Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rats liver extract. Jpn. J. Cancer Res., 78: 748-755, 1987.
28. Peters, G. J., Van Groeningen, C. J., Schomage, J. H., Gall, H. E., Noordhuis, P., De Vries, M., Van Kullenburg, A. B. P., and Hanauske, A-R. Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil (5-FU)-based antineoplastic agent. Proc. Am. Soc. Clin. Oncol., 16: 227a, 1997.
29. Rustum, Y. M., Cao, S., Shirasaka, T., and Taguchi, T. A new 5-fluorouracil prodrug, S-1, orally bioavailable with high therapeutic index in model system active in phase II clinical trials. Proc. Am. Soc. Clin. Oncol., 16: 227a, 1997.
30. Cao, S., Shirasaka, T., and Rustum, Y. M. Therapeutic selectivity of S-1, a new oral formulation of ftorafur (FT), 5-chloro-2,4-dihydroxypyridine (CDHP) and oxonic acid (Oxo) in rats bearing advanced colorectal carcinoma., Proc. Am. Assoc. Cancer Res., 36: 290, 1995.
31. Danhauser, L. L., and Rustum, Y. M. A method for continuous drug infusion in unrestrained rats: its application in evaluating the toxicity of 5-fluorouracil/thymidine combination. J. Lab. Clin. Med., 93: 1047-1053, 1979.
32. Cao, S., Frank, C., and Rustum, Y. M. Role of fluoropyrimidine schedule and (6R,S) leucovorin dose in a preclinical animal model of colorectal carcinoma. J. Natl. Cancer Inst., 88: 430-436, 1996.
33. Spears, C. P., Shahinian, A. H., Moran, R. G., Heidelberger, C., and Corbett, T. H. In vivo kinetics of thymidylate synthetase inhibition in 5-fluorouracil-sensitive and -resistant murine colon adenocarcinomas. Cancer Res., 42: 450-456, 1982.
34. Davis, S. T., Joyner, S. S., Baccanari, D. P., and Spector, T. 5-Ethynyluracil (776C85): protection from 5-fluorouracil-induced neurotoxicity in dogs. Biochem. Pharmacol., 48: 233-236, 1994.
35. Inada, T., Ichikawa, A., Kubota, T., Ogata, Y., Moossa, A., and Hoffman, R. M. 5-FU-induced apoptosis correlates with efficacy against human gastric and colon cancer xenografts in nude mice. Anticancer Res., 17: 1965-1972, 1997.
36. Sugamura, K., Makino, M., Shiria, H., Kimura, O., Maeta, M., Itoh, H., and Kaibara, N. Enhanced induction of apoptosis of human gastric carcinoma cells after preoperative treatment with 5-fluorouracil. Cancer (Phila.), 79: 12-17, 1997.